Cambridge Healthtech Institute’s 3rd Annual

Small Molecules for Cancer Immunotherapy
( 癌症免疫疗法的小分子药物 )

Design of New Molecules and Combinations for Immuno-oncology Targets


First-generation cancer immunotherapy agents being developed or approved were either engineered T cells targeting tumors or antibody-based biologics targeting the immune checkpoint cascade. However, novel second and third-generation drugs that are in preclinical or early-stage clinical development are small molecules that act on intracellular targets and receptors affecting immuno-modulatory pathways in cancer. Cambridge Healthtech Institute’s 3rd Annual Small Molecules for Cancer Immunotherapy conference brings together discovery chemists and biologists to talk about these new intracellular oncology targets and immuno-modulatory small molecule inhibitors that are being developed to act alone or in combination with existing treatments. IDO1, USP7, STING, TIM-3, VISTA, LAG-3, KIR, bromodomains are examples of some oncology targets that are being actively pursued by small molecule drugs. The development of programs around these targets and discussions on translational challenges, response rates, drug resistance and safety will certainly be covered in this conference.

Coverage will include, but is not limited to:


  • Update on next-generation small molecule immuno-oncology drugs in development
  • Identification of immune pathways that can be solely or optimally targeted by small molecules
  • Emerging immuno-oncology target classes for small molecule intervention
  • Design of novel combination therapies using small molecules along with biologics or cell therapy
  • Development of new molecular class of small molecules such as synthetic antibody mimics

* 活动内容有可能不事先告知作更动及调整。